208 related articles for article (PubMed ID: 37407956)
21. Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Burkhoff D; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE
Circ Heart Fail; 2022 Mar; 15(3):e009156. PubMed ID: 34743533
[TBL] [Abstract][Full Text] [Related]
22. Timing of SGLT2i initiation after acute myocardial infarction.
von Lewinski D; Kolesnik E; Aziz F; Benedikt M; Tripolt NJ; Wallner M; Pferschy PN; von Lewinski F; Schwegel N; Holman RR; Oulhaj A; Moertl D; Siller-Matula J; Sourij H
Cardiovasc Diabetol; 2023 Sep; 22(1):269. PubMed ID: 37777743
[TBL] [Abstract][Full Text] [Related]
23. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
24. Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure.
Kolwelter J; Bosch A; Jung S; Stabel L; Kannenkeril D; Ott C; Bramlage P; Schiffer M; Achenbach S; Schmieder RE
ESC Heart Fail; 2021 Dec; 8(6):5327-5337. PubMed ID: 34544205
[TBL] [Abstract][Full Text] [Related]
25. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jensen J; Omar M; Kistorp C; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Faber J; Malik ME; Fosbøl EL; Bruun NE; Forman JL; Jensen LT; Møller JE; Schou M
Lancet Diabetes Endocrinol; 2021 Feb; 9(2):106-116. PubMed ID: 33357505
[TBL] [Abstract][Full Text] [Related]
26. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
[TBL] [Abstract][Full Text] [Related]
27. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA; Angermann CE; Teerlink JR; Collins SP; Kosiborod M; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Tromp J; Borleffs CJW; Ma C; Comin-Colet J; Fu M; Janssens SP; Kiss RG; Mentz RJ; Sakata Y; Schirmer H; Schou M; Schulze PC; Spinarova L; Volterrani M; Wranicz JK; Zeymer U; Zieroth S; Brueckmann M; Blatchford JP; Salsali A; Ponikowski P
Nat Med; 2022 Mar; 28(3):568-574. PubMed ID: 35228754
[TBL] [Abstract][Full Text] [Related]
28. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
29. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
30. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
[TBL] [Abstract][Full Text] [Related]
31. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
32. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
33. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
[TBL] [Abstract][Full Text] [Related]
34. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
35. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Pietschner R; Kolwelter J; Bosch A; Striepe K; Jung S; Kannenkeril D; Ott C; Schiffer M; Achenbach S; Schmieder RE
Cardiovasc Diabetol; 2021 Nov; 20(1):219. PubMed ID: 34753480
[TBL] [Abstract][Full Text] [Related]
36. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
Refardt J; Imber C; Sailer CO; Jeanloz N; Potasso L; Kutz A; Widmer A; Urwyler SA; Ebrahimi F; Vogt DR; Winzeler B; Christ-Crain M
J Am Soc Nephrol; 2020 Mar; 31(3):615-624. PubMed ID: 32019783
[TBL] [Abstract][Full Text] [Related]
37. Baseline neutrophil-to-lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling.
Verma R; Moroney M; Hibino M; Mazer CD; Connelly KA; Yan AT; Quan A; Teoh H; Verma S; Puar P
ESC Heart Fail; 2023 Jun; 10(3):2127-2133. PubMed ID: 37038617
[TBL] [Abstract][Full Text] [Related]
38. Neutrophil-to-lymphocyte Ratio and Its Relation with Markers of Inflammation and Myocardial Necrosis in Patients with Acute Coronary Syndrome.
Tahto E; Jadric R; Pojskic L; Kicic E
Med Arch; 2017 Oct; 71(5):312-315. PubMed ID: 29284896
[TBL] [Abstract][Full Text] [Related]
39. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
